Bank of America
ACRS icon

Bank of America’s Aclaris Therapeutics ACRS Stock Holding History

Bank of America’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$584K Buy
110,412
+30,873
+39% +$138K ﹤0.01% 4899
2026
Q1 		$298K Buy
79,539
+15,018
+23% +$50.7K ﹤0.01% 5158
2025
Q4 		$194K Sell
64,521
-10,670
-14% -$27K ﹤0.01% 5361
2025
Q3 		$143K Buy
75,191
+2,596
+4% +$4.53K ﹤0.01% 6436
2025
Q2 		$103K Sell
72,595
-95,074
-57% -$129K ﹤0.01% 6509
2025
Q1 		$257K Sell
167,669
-37,796
-18% -$80.6K ﹤0.01% 6047
2024
Q4 		$510K Buy
205,465
+196,708
+2,246% +$489K ﹤0.01% 5524
2024
Q3 		$10.1K Buy
8,757
+2,262
+35% +$2.77K ﹤0.01% 6897
2024
Q2 		$7.14K Sell
6,495
-19,152
-75% -$22.5K ﹤0.01% 6954
2024
Q1 		$31.8K Sell
25,647
-99,740
-80% -$119K ﹤0.01% 6647
2023
Q4 		$132K Buy
125,387
+73,689
+143% +$225K ﹤0.01% 6265
2023
Q3 		$354K Buy
51,698
+8,930
+21% +$76.3K ﹤0.01% 5551
2023
Q2 		$444K Sell
42,768
-27,095
-39% -$245K ﹤0.01% 5360
2023
Q1 		$565K Sell
69,863
-11,255
-14% -$143K ﹤0.01% 5308
2022
Q4 		$1.28M Buy
81,118
+9,301
+13% +$150K ﹤0.01% 4642
2022
Q3 		$1.13M Sell
71,817
-24,880
-26% -$392K ﹤0.01% 4791
2022
Q2 		$1.35M Buy
96,697
+65,383
+209% +$916K ﹤0.01% 4638
2022
Q1 		$540K Sell
31,314
-29,344
-48% -$400K ﹤0.01% 5778
2021
Q4 		$882K Buy
60,658
+38,506
+174% +$583K ﹤0.01% 5408
2021
Q3 		$399K Buy
22,152
+7,209
+48% +$116K ﹤0.01% 5808
2021
Q2 		$262K Buy
+14,943
New +$339K ﹤0.01% 5898
2020
Q4 		– Sell
-44
Closed – – 7063
2020
Q3 		$0 Sell
44
-4,344
-99% -$9.72K ﹤0.01% 6851
2020
Q2 		$7K Buy
4,388
+3,496
+392% +$4.68K ﹤0.01% 6508
2020
Q1 		$1K Sell
892
-17,108
-95% -$23.3K ﹤0.01% 6691
2019
Q4 		$35K Sell
18,000
-6,671
-27% -$11.1K ﹤0.01% 6358
2019
Q3 		$27K Sell
24,671
-43,264
-64% -$61.4K ﹤0.01% 6513
2019
Q2 		$149K Sell
67,935
-53,036
-44% -$289K ﹤0.01% 5795
2019
Q1 		$725K Buy
120,971
+75,626
+167% +$501K ﹤0.01% 4761
2018
Q4 		$335K Buy
45,345
+28,803
+174% +$297K ﹤0.01% 5189
2018
Q3 		$240K Buy
16,542
+10,852
+191% +$186K ﹤0.01% 5382
2018
Q2 		$113K Sell
5,690
-5,373
-49% -$99.3K ﹤0.01% 5733
2018
Q1 		$194K Buy
11,063
+3,637
+49% +$77.1K ﹤0.01% 5384
2017
Q4 		$184K Sell
7,426
-125,677
-94% -$3.06M ﹤0.01% 5445
2017
Q3 		$3.44M Buy
133,103
+47,327
+55% +$1.27M ﹤0.01% 3520
2017
Q2 		$2.33M Buy
85,776
+83,735
+4,103% +$2.28M ﹤0.01% 3754
2017
Q1 		$61K Buy
2,041
+280
+16% +$8.07K ﹤0.01% 5829
2016
Q4 		$48K Buy
1,761
+1,155
+191% +$29.4K ﹤0.01% 5947
2016
Q3 		$15K Buy
606
+436
+256% +$9.25K ﹤0.01% 6229
2016
Q2 		$3K Buy
+170
New +$3.37K ﹤0.01% 6789
2016
Q1 		– Sell
-139
Closed -$4K – 6949
2015
Q4 		$4K Buy
+139
New +$2.71K ﹤0.01% 6927

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Bank of America's ACRS Position: Q2 2026 in Review

Bank of America increased its Aclaris Therapeutics (ACRS) stake by 39% in Q2 2026, buying an estimated $138K and bringing the position to 110,412 shares worth $584K. The position accounts for ﹤0.01% of the portfolio, ranked #4899.

Bank of America first reported a position in ACRS in Q4 2015 and has held it in 40 quarters since. The position peaked at $3.44M in Q3 2017. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Bank of America held 110,412 shares of Aclaris Therapeutics worth $584K as of Q2 2026.
  • Bank of America bought 30,873 Aclaris Therapeutics shares in Q2 2026, an estimated $138K.
  • Aclaris Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #4899 holding.
  • Bank of America first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 40 quarters since.
  • Bank of America's Aclaris Therapeutics position peaked at $3.44M in Q3 2017.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.